MDCX

Medicus Pharma Ltd

0.3504

Jul 21 • 07:50AM ET -0.0036 (-1.02%)

Healthcare Drug Manufacturers - General Canada Nano NASD

Peers: MIRA NSRX AMRN SCLX CPHI RMTI BGM SCYX CPIX CTOR

Index	-
Market Cap	19.86M
Enterprise Value	17.19M
Income	-37.06M
Sales	0.00M
Book/sh	0.02
Cash/sh	0.08
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	16
IPO	Jan 26, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	14.75
P/C	4.35
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.22
Current Ratio	1.22
Debt/Eq	1.92
LT Debt/Eq	0.03
Option/Short	No / Yes

EPS (ttm)	-1.78
EPS next Y	-0.39
EPS next Q	-0.13
EPS this Y	81.14%
EPS next Y	23.87%
EPS next 5Y	47.64%
EPS past 3/5Y	-129.96% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-73.57%
Sales Y/Y TTM	-
EPS Q/Q	23.20%
Sales Q/Q	-
Earnings	May 14 AMC
EPS/Sales Surpr.	-61.46% -

Insider Own	12.97%
Insider Trans	0.00%
Inst Own	19.55%
Inst Trans	-5.68%
ROA	-616.59%
ROE	-2336.00%
ROIC	-2903.17%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-15.19%
SMA50	-4.18%
SMA200	-68.99%
Trades

Shs Outstand	40.00M
Shs Float	10.28M
Short Float	10.17%
Short Ratio	0.49
Short Interest	1.05M
52W High	3.13 -88.81%
52W Low	0.25 40.16%
Volatility	9.26% 11.87%
ATR (14)	0.04
RSI (14)	43.58
Beta	-0.72
Rel Volume	0.09
Avg Volume	2.15M
Volume	9,384

Perf Week	-3.68%
Perf Month	-23.41%
Perf Quarter	1.86%
Perf Half Y	-74.79%
Perf YTD	-77.10%
Perf Year	-88.55%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	5.67
Prev Close	0.35
Price	0.35
Change	-1.02%

Jul-18-26 12:24PM	Medicus Pharma CEO details Teverelix progress ICYMI (Proactive)
Jul-17-26 12:48PM	Medicus Pharma advances Phase 2 study following FDA and IRB feedback (Proactive) -7.44%
Jul-16-26 08:37AM	Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval (Proactive) +16.53%
07:30AM	Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix Novel Study in Acute Urinary Retention (GlobeNewswire)
Jun-22-26 07:30AM	Medicus Pharma to Showcase SkinJect Registrational Strategy and Teverelix Precision Medicine Program at Bio International 2026 (GlobeNewswire)
09:00AM	Loading…
Jun-20-26 09:00AM	Medicus Pharma advances Teverelix in prostate cancer - ICYMI (Proactive)
Jun-15-26 08:47AM	Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome (Proactive) -5.24%
07:30AM	Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect in Gorlin Syndrome (GlobeNewswire)
Jun-11-26 08:50AM	Medicus Pharma files IND for genomics-enabled endometriosis trial in UAE (Proactive)
07:30AM	Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix in Endometriosis utilizing the Emirati Genome Program (GlobeNewswire)
Jun-08-26 08:50AM	Medicus Pharma submits EU clinical trial modification for prostate cancer drug Teverelix (Proactive)
07:30AM	Medicus Pharma Advances Teverelix Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission (GlobeNewswire)
Jun-06-26 11:26AM	Medicus Pharma advances SkinJect for Gorlin syndrome ICYMI (Proactive)
Jun-05-26 11:43AM	Medicus Pharma advances SkinJect toward registrational trial for rare Gorlin Syndrome (Proactive) -6.32%
Jun-03-26 09:09AM	Medicus Pharma advances SkinJect program with FDA submission targeting Gorlin Syndrome (Proactive) +6.97%
08:00AM	Loading…
08:00AM	Medicus Pharma Advances SkinJect into Registrational Development for Gorlin Syndrome (GlobeNewswire)
May-28-26 09:25AM	Medicus Pharma secures up to $22M in non-dilutive financing facility (Proactive) +6.74%
08:00AM	Medicus Pharma Announces $22 Million Non-Dilutive Financing (GlobeNewswire)
May-15-26 08:28AM	Medicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progress (Proactive) -10.68%
May-14-26 04:30PM	Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +5.28%
May-06-26 12:12PM	Medicus Pharma reports strong Phase 2 dose response in skin cancer study (Proactive) +20.95%
09:27AM	Medicus Pharma highlights positive dose-response in updated skin cancer trial results (Proactive)
08:01AM	Nasdaq and S&P surge to new records on Iran deal hopes, AMD and Disney gains (Proactive)
07:30AM	Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response (GlobeNewswire)
Apr-27-26 09:23AM	Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome (Proactive) -5.68%
07:30AM	Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill (GlobeNewswire)
07:30AM	Dow leads markets lower as investors gear up for mega-cap earnings, Fed meeting (Proactive)
Apr-24-26 04:15PM	Medicus Pharma advances Skinject in rare disease ICYMI (Proactive) -5.18%
Apr-20-26 11:32AM	Medicus Pharma files Orphan Drug application for SkinJect in rare skin Cancer indication (Proactive)
Apr-17-26 09:02AM	Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder (Proactive) +16.98%
08:00AM	Loading…
08:00AM	Dow rockets higher as Strait of Hormuz stays open, talks eyed (Proactive)
08:00AM	Dow powers higher as oil slump, easing tensions lift stocks (Proactive)
07:30AM	Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect in Gorlin Syndrome (GlobeNewswire)
Apr-16-26 10:30AM	BC-Most Active Stocks (Associated Press)
Apr-15-26 10:30AM	BC-Most Active Stocks (Associated Press) -25.04%
07:30AM	Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression (GlobeNewswire)
07:29AM	Nasdaq pushes ahead but Dow Jones slips, Trump eyes more Iran talk (Proactive)
05:07AM	Medicus Pharma to present new Teverelix data at upcoming endocrinology meeting (Proactive)
Apr-10-26 01:43PM	Medicus Pharma gives Teverelix Phase 2 FDA update ICYMI (Proactive) -6.33%
Apr-06-26 04:15PM	Nasdaq leads Wall Street higher in the face of Iran tensions and oil volatility (Proactive) +9.82% -8.33%
11:26AM	Medicus Pharma submits optimized Phase 2 study design for Teverelix (Proactive)
10:38AM	Medicus Pharma submits optimized Phase 2 Teverelix trial protocol to FDA (Proactive)
07:30AM	Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention (GlobeNewswire)
Apr-04-26 10:00AM	Medicus Pharma SkinJect Phase 2 study data endorsed by independent expert - ICYMI (Proactive)
Apr-01-26 03:43PM	Nasdaq and Dow continue rally as Trump says Iran asks for ceasefire (Proactive) -8.50%
09:48AM	Medicus Pharma eyes registrational study for SkinJect after positive Phase 2 data (Proactive)
07:30AM	Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset (GlobeNewswire)
Mar-30-26 04:22PM	Dow Jones alone in the green, Nasdaq slumps as Trump says Iran talks 'serious' (Proactive) -9.64% +12.89%
03:44PM	Dow Jones alone in the green as Trump says Iran talks 'serious' (Proactive)
08:38AM	Medicus Pharma highlights independent support for Phase 2 SkinJect results (Proactive)
07:30AM	Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate (GlobeNewswire)
Mar-26-26 08:36AM	Medicus Pharma advances SkinJect, Teverelix programs, eyes catalyst-rich 2026 (Proactive) -5.71%
07:30AM	Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan (GlobeNewswire)
Mar-25-26 04:30PM	Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Mar-18-26 07:30AM	Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst (ACCESSWIRE)
Mar-16-26 07:30AM	Medicus Pharma Announces SkinJect Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26 (GlobeNewswire)
Mar-14-26 09:00AM	Medicus Pharma CEO discusses promising Phase 2 SkinJect results - ICYMI (Proactive)
Mar-10-26 07:30AM	Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum (ACCESSWIRE)
Mar-09-26 11:10AM	Medicus Pharma provides additional Phase 2 data for SkinJect Cancer therapy (Proactive) +34.26%
08:39AM	Medicus says Phase 2 data supports further development of SkinJect therapy for skin cancer (Proactive)
07:30AM	Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect Dataset (GlobeNewswire)
Mar-07-26 08:00AM	Medicus Pharma CEO discusses Phase 2 skin cancer results - ICYMI (Proactive)
Mar-05-26 03:49PM	Dow Jones continues to fall as oil prices climb (Proactive) -50.88%
11:41AM	Medicus Pharma reports positive phase 2 results for microneedle skin cancer treatment (Proactive)
09:13AM	Medicus Pharma Stock Swings After Skin Cancer Treatment Results (Benzinga)
08:35AM	Medicus Pharma reports positive Phase 2 results for microneedle treatment for basal cell carcinoma (Proactive)
07:30AM	Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200µg Cohort (GlobeNewswire)
Mar-03-26 07:30AM	Medicus Pharma To Participate in the 38th Annual Roth Conference (GlobeNewswire)
Feb-14-26 11:30AM	Medicus Pharmas Teverelix Phase 2b trial cleared by FDA - ICYMI (Proactive)
Feb-12-26 11:39AM	Medicus Pharma cleared to launch Phase 2b Teverelix study in Prostate Cancer (Proactive)
07:30AM	Medicus Pharma on Bloomberg World (ACCESSWIRE)
Feb-10-26 09:32AM	Medicus Pharma receives FDA clearance to proceed with Phase 2b prostate cancer study (Proactive)
07:30AM	Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk (GlobeNewswire)
Jan-23-26 07:30AM	Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony (ACCESSWIRE)
Jan-22-26 07:30AM	Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix Long-Term Economic and Development Profile (GlobeNewswire)
Jan-20-26 07:30AM	Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026 (GlobeNewswire)
Jan-12-26 07:30AM	Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women (GlobeNewswire) -5.81%
Jan-05-26 07:30AM	Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates (GlobeNewswire)
Dec-22-25 07:30AM	Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform (ACCESSWIRE) -7.69%
Dec-15-25 07:30AM	Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin (GlobeNewswire)
Dec-05-25 03:20PM	Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement (ACCESSWIRE) +6.77%
Dec-01-25 08:00AM	Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President (ACCESSWIRE) -10.23%
Nov-25-25 08:16AM	Maxim Group Reaffirms Buy on Medicus Pharma Ltd (MDCX) With $20 Target (Insider Monkey)
Nov-24-25 08:00AM	Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers (GlobeNewswire) -7.04%
Nov-17-25 07:30AM	Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin (ACCESSWIRE)
Nov-14-25 05:00PM	Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights (ACCESSWIRE)
Nov-13-25 07:30AM	Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin (ACCESSWIRE) -5.44%
Oct-29-25 07:30AM	Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome (ACCESSWIRE)
07:30AM	Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT in Patients with Gorlin Syndrome (GlobeNewswire)
Oct-22-25 07:30AM	Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin (ACCESSWIRE)
Oct-14-25 08:07AM	The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets (ACCESSWIRE)
Oct-13-25 07:30AM	Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025 (ACCESSWIRE) -6.45%
Oct-07-25 07:30AM	Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE (ACCESSWIRE)
Sep-29-25 07:30AM	Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject (ACCESSWIRE)
Sep-24-25 09:26AM	Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX) (Newsfile) -8.93%
07:30AM	Medicus Pharma Ltd. To Present at Brookline Capital Markets (ACCESSWIRE)
Sep-18-25 07:30AM	Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing (ACCESSWIRE)
Sep-08-25 07:30AM	Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) (ACCESSWIRE) +11.17%
Sep-02-25 07:30AM	Medicus Pharma Ltd. Completes Acquisition of Antev Limited (Newsfile) +7.22%
Aug-21-25 07:30AM	Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights (Newsfile) +20.10%

Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. It develops a product, SkinJectTM, with an indication for basal cell carcinoma. The company was founded on April 30, 2008 and is headquartered in Toronto, Canada.

M.D.Dr. Raza Bokhari M.B.A.

F.A.C.S.Dr. Edward J. Brennan Jr.

Chief Medical OfficerDr. Faisal Mehmud M.D.

Chief Operating OfficerMr. Andrew Alasdair Smith

Senior Vice President of Investor RelationsMs. Anna Baran-Djokovic J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Quinlan James P.	Chief Financial Officer	Aug 13 '25	Option Exercise	1.08	145,000	156,250	274,147	Aug 14 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MDCX

Medicus Pharma Ltd

Upgrade your Finviz experience